• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BiomX Inc.

    3/25/24 3:35:52 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    SC 13G 1 tm249654d1_sc13g.htm SC 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    (Amendment No. )*

     

    BiomX Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    09090D103

    (CUSIP Number)

     

    AMR Action Fund, L.P.
    c/o AMR Action Fund GP, LLC

    225 Franklin Street, Suite 1750
    Boston, MA 02110
    Tel 862-325-3580

     

    With a copy to:

     

    Derek Stoldt

    Arnold & Porter Kaye Scholer LLP

    250 West 55th Street

    New York, NY 10019

    Tel 212-836-8000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    March 15, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

      * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No. 09090D103 13G Page 2 of 10 Pages

    1.

    NAMES OF REPORTING PERSON

     

    AMR Action Fund, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

     

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,054,870 (1)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,054,870 (1)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,054,870 (1)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1) The number of shares of Common Stock beneficially owned by the Reporting Person does not include (i) an aggregate of 42,337,000 shares of Common Stock underlying 42,337 shares of Series X Preferred Stock, which will become convertible into Common Stock (subject to a beneficial ownership limitation), if at all, upon the occurrence of certain conditions, or (ii) an aggregate of 15,145,647 shares of Common Stock underlying warrants that will become exercisable for Common Stock (subject to a beneficial ownership limitation), if at all, upon the occurrence of certain conditions.

     

     

     

     

    CUSIP No. 09090D103 13G Page 3 of 10 Pages

    1.

    NAMES OF REPORTING PERSON

     

    AMR Action Fund GP, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

     

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER


    3,054,870(2)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER


    3,054,870(2)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,054,870(2)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (2) Consists of shares of common stock held by AMR Action Fund, L.P. See Footnote 1.

     

     

     

     

    CUSIP No. 09090D103 13G Page 4 of 10 Pages

    1.

    NAMES OF REPORTING PERSON

     

    AMR Action Fund, SCSp

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

     

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER


    3,054,870 (3)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER


    3,054,870 (3)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,054,870(3)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (3) The number of shares of Common Stock beneficially owned by the Reporting Person does not include (i) an aggregate of 42,337,000 shares of Common Stock underlying 42,337 shares of Series X Preferred Stock, which will become convertible into Common Stock (subject to a beneficial ownership limitation), if at all, upon the occurrence of certain conditions, or (ii) an aggregate of 15,145,647 shares of Common Stock underlying warrants that will become exercisable for Common Stock (subject to a beneficial ownership limitation), if at all, upon the occurrence of certain conditions.

     

     

     

     

    CUSIP No. 09090D103 13G Page 5 of 10 Pages

    1.

    NAMES OF REPORTING PERSON

     

    AMR Action Fund, S.a r.l.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

     

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER


    3,054,870 (4)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER


    3,054,870 (4)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,054,870 (4)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (4) Consists of shares of common stock held by AMR Action Fund, SCSp. See Footnote 1.

     

     

     

     

    Item 1.

     

    (a)

    Name of Issuer

    BiomX Inc. (the “Issuer”)

       
    (b)

    Address of Issuer’s Principal Executive Offices
    22 Einstein Street, Floor 4

    Ness Ziona 7414003, Israel

     

    Item 2.

     

    (a) Name of Person Filing:

     

    This Statement of Beneficial Ownership on Schedule 13G, filed on March 25, 2024 (the “Statement”) is being filed by each of:

     

    (i) AMR Action Fund, L.P.;

     

    (ii) AMR Action Fund GP, LLC;

     

    (iii) AMR Action Fund, SCSp; and

     

    (iv) AMR Action Fund, S.a.r.l.

     

    (each a “Reporting Person” and, collectively, the “Reporting Persons”). This Schedule 13G is being filed pursuant to a Joint Filing Agreement (the “Joint Filing Agreement”), a copy of which is filed herewith as Exhibit 99.1.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

     

    The principal business office of each of the Reporting Persons are:

     

    AMR Action Fund, L.P., c/o AMR Action Fund GP, LLC, 225 Franklin Street, Suite 1750, Boston, MA 02110

    AMR Action Fund GP, LLC, 225 Franklin Street, Suite 1750, Boston, MA 02110

    AMR Action Fund, SCSp, c/o AMR Action Fund GP, S.a.r.l., 16 Rue Eugene Ruppert, L-2543 Luxembourg, Grand Duchy of Luxembourg

    AMR Action Fund GP, S.a.r.l., 16 Rue Eugene Ruppert, L-2543 Luxembourg, Grand Duchy of Luxembourg

     

    (c)

    Citizenship:


    AMR Action Fund GP, S.a.r.l., and AMR Action Fund, SCSp are organized under the laws of Luxembourg. AMR Action Fund GP, LLC and AMR Action Fund, L.P. are organized under the laws of the State of Delaware.

       
    (d)

    Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (the “Shares”)

       
    (e)

    CUSIP Number

     

    09090D103

     

     

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) (b) Number and percentage of Issuer Shares beneficially owned by each Reporting Person:

     

    Reporting Person  Number of Shares   Percentage of Class 
    AMR Action Fund, L.P.   3,054,870    5.5%
    AMR Action Fund GP, LLC   3,054,870    5.5%
    AMR Action Fund, SCSp   3,054,870    5.5%
    AMR Action Fund GP, S.a.r.l.   3,054,870    5.5%

     

    With respect to each of the Reporting Persons:

     

    (a) Number of shares as to which the Reporting Person has:
         
      (i)

    Sole power to vote or to direct the vote:

    AMR Action Fund, L.P.: 0

    AMR Action Fund GP, LLC: 0

    AMR Action Fund, SCSp: 0

    AMR Action Fund GP, S.a.r.l.: 0

     

     

     

     

      (ii)

    Shared power to vote or to direct the vote:

    AMR Action Fund, L.P.: 3,054,870

    AMR Action Fund GP, LLC: 3,054,870

    AMR Action Fund, SCSp: 3,054,870

    AMR Action Fund GP, S.a.r.l.: 3,054,870

         
      (iii)

    Sole power to dispose or to direct the disposition of:

    AMR Action Fund, L.P.: 0

    AMR Action Fund GP, LLC: 0

    AMR Action Fund, SCSp: 0

    AMR Action Fund GP, S.a.r.l.: 0

         
      (iv)

    Shared power to dispose or to direct the disposition of:

    AMR Action Fund, L.P.: 3,054,870

    AMR Action Fund GP, LLC: 3,054,870

    AMR Action Fund, SCSp: 3,054,870

    AMR Action Fund GP, S.a.r.l.: 3,054,870

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) - (c) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. AMR Action Fund, L.P. is the record owner of 2,267,963 shares of the Issuer’s common stock. AMR Action Fund GP, LLC is the general partner of AMR Action Fund, L.P. and may be deemed to have voting and dispositive control over the shares of common stock held by AMR Action Fund, L.P. AMR Action Fund, SCSp is the record owner of 786,907 shares of the Issuer’s common stock. AMR Action Fund GP, S.a.r.l. is the general partner of AMR Action Fund, SCSp and may be deemed to have voting and dispositive control over the shares of common stock held by AMR Action Fund, SCSp. Each of AMR Action Fund GP, LLC and AMR Action Fund GP, S.a.r.l. disclaim beneficial ownership of the shares of common stock.

     

    Throughout this report, the percentage of outstanding shares of Common Stock beneficially owned by the Reporting Persons reflects (i) 46,055,109 shares of Common Stock outstanding as of March 4, 2024, based on representations made by the Company in that certain Agreement and Plan of Merger, dated March 6, 2024 (the “Merger Agreement”), by and among the Issuer, BTX Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer, BTX Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer, and Adaptive Phage Therapeutics, Inc., a Delaware corporation, plus (ii) 9,164,967 additional shares of Common Stock issued pursuant to the Merger Agreement based on the Company’s Current Report on Form 8-K, filed on March 6, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    Item 10. Certification.

     

    Each of the Reporting Persons hereby certifies as follows:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    AMR ACTION FUND, L.P.

     

    By: AMR Action Fund GP, LLC, its General Partner

     

    /s/ Henry Skinner  
    Name:  Henry Skinner  
    Title: Chief Executive Officer  

     

    AMR ACTION FUND GP, LLC

     

    /s/ Henry Skinner  
    Name:  Henry Skinner  
    Title: Chief Executive Officer  

     

    AMR ACTION FUND, SCSp

     

    By: AMR Action Fund GP, S.a.r.l., its General Partner

     

    /s/ Henry Skinner  
    Name:  Henry Skinner  
    Title: Class A Manager  

     

    AMR ACTION FUND GP, S.a.r.l.

     

    /s/ Henry Skinner  
    Name:  Henry Skinner  
    Title: Class A Manager  

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit    
    99.1   Joint Filing Agreement

     

     

     

    Get the next $PHGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

      NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure

      4/1/25 6:30:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

      BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

      3/31/25 6:30:57 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

      11/16/21 9:23:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

      10/19/21 8:36:54 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on BiomX with a new price target

      HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

      10/18/21 12:27:44 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by *Director by Deputization Flynn James E

      4 - BiomX Inc. (0001739174) (Issuer)

      4/23/25 5:49:02 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 4 filed by Director Merril Gregory Louis

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:24:29 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Development Officer Bassan Merav was granted 79,597 shares (SEC Form 4)

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:11:31 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by BiomX Inc.

      SCHEDULE 13G - BiomX Inc. (0001739174) (Subject)

      5/8/25 7:39:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by BiomX Inc.

      424B3 - BiomX Inc. (0001739174) (Filer)

      4/24/25 8:47:36 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by BiomX Inc.

      EFFECT - BiomX Inc. (0001739174) (Filer)

      4/24/25 12:15:07 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      11/13/24 5:14:46 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      11/4/24 4:05:35 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      10/28/24 4:01:32 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    See more
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Telum Therapeutics appoints Dr. Subhendu Basu as CEO

      Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

      3/19/24 5:00:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

      10/18/23 8:00:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Financials

    Live finance-specific insights

    See more
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

      BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

      3/31/25 6:30:57 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

      NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company's website at www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expec

      3/19/25 12:35:31 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care